REM Behavior Disorder
8
1
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
25.0%
2 terminated out of 8 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
INSIGHT: Insomnia, Nightmares, and Sympathetic Hyperactivity Intervention
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System
Subcortical Oscillations in Human Sleep Dysregulation
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Mainz Register of Patients With Sleep Disorders